Document:

EX-10.11

 Exhibit 10.11 

PREVAIL THERAPEUTICS INC. 

2019 EMPLOYEE STOCK PURCHASE PLAN 

ADOPTED BY THE BOARD OF DIRECTORS:
JUNE 6, 2019 
 APPROVED BY THE STOCKHOLDERS:
JUNE 6, 2019 
 IPO DATE: JUNE    , 2019 

1.    GENERAL; PURPOSE. 

(a)    The Plan provides a means by which Eligible Employees of the Company and certain designated Related
Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. 

(b)    The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the
services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related Corporations. 

2.    ADMINISTRATION. 

(a)    The Board will administer the Plan unless and until the Board delegates administration of the Plan to a
Committee or Committees, as provided in Section 2(c). 
 (b)    The Board will have the power, subject to,
and within the limitations of, the express provisions of the Plan: 
 (i)    To determine how and when Purchase
Rights will be granted and the provisions of each Offering (which need not be identical). 
 (ii)    To designate
from time to time which Related Corporations of the Company will be eligible to participate in the Plan. 

(iii)    To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and
regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective. 

(iv)    To settle all controversies regarding the Plan and Purchase Rights granted under the Plan. 

(v)    To suspend or terminate the Plan at any time as provided in Section 12. 

(vi)    To amend the Plan at any time as provided in Section 12. 

 (vii)    Generally, to exercise such powers and to perform such
acts as it deems necessary or expedient to promote the best interests of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan. 

(viii)    To adopt such rules, procedures and sub-plans relating to the
operation and administration of the Plan as are necessary or appropriate under applicable local laws, regulations and procedures to permit or facilitate participation in the Plan by Employees who are foreign nationals or employed or located outside
the United States. 
 (c)    The Board may delegate some or all of the administration of the Plan to a Committee
or Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to
delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not
inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the
powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the Plan.

 (d)    All determinations, interpretations and constructions made by the Board in good faith will not be
subject to review by any person and will be final, binding and conclusive on all persons. 
 3.    SHARES
OF COMMON STOCK SUBJECT TO THE PLAN. 

(a)    Subject to the provisions of Section 11(a) relating to Capitalization Adjustments, the maximum number of
shares of Common Stock that may be issued under the Plan will not exceed 330,000 shares of Common Stock, plus the number of shares of Common Stock that are automatically added on January 1st of
each year for a period of up to ten years, commencing on the first January 1 following the year in which the IPO Date occurs and ending on (and including) January 1, 2029, in an amount equal to the lesser of (i) 1% of the total number of
shares of Capital Stock outstanding on December 31st of the preceding calendar year, and (ii) 1,500,000 shares of Common Stock. Notwithstanding the foregoing, the Board may act prior to the first
day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be
a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence. 

(b)    If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of
Common Stock not purchased under such Purchase Right will again become available for issuance under the Plan. 

(c)    The stock purchasable under the Plan will be shares of authorized but unissued or reacquired Common Stock,
including shares repurchased by the Company on the open market. 

  
 2 

 4.    GRANT OF PURCHASE
RIGHTS; OFFERING. 
 (a)    The Board may from time to time grant or provide for
the grant of Purchase Rights to Eligible Employees under an Offering (consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and
conditions as the Board will deem appropriate, and will comply with the requirement of Section 423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering
shall be incorporated by reference into the Plan and treated as part of the Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the
document comprising the Offering or otherwise) the period during which the Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8,
inclusive. 
 (b)    If a Participant has more than one Purchase Right outstanding under the Plan, unless he or
she otherwise indicates in forms delivered to the Company: (i) each form will apply to all of his or her Purchase Rights under the Plan, and (ii) a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if
different Purchase Rights have identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise
prices) will be exercised. 
 (c)    The Board will have the discretion to structure an Offering so that if the
Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i) that
Offering will terminate immediately as of that first Trading Day, and (ii) the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. 

5.    ELIGIBILITY. 

(a)    Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance
with Section 2(b), to Employees of a Related Corporation. Except as provided in Section 5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company
or the Related Corporation, as the case may be, for such continuous period preceding such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two years. In addition,
the Board may (unless prohibited by law) provide that no Employee will be eligible to be granted Purchase Rights under the Plan unless, on the Offering Date, such Employee’s customary employment with the Company or the Related Corporation is
more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may determine consistent with Section 423 of the Code. The Board may also exclude from participation in the Plan or any Offering
Employees who are “highly compensated employees” (within the meaning of Section 414(q) of the Code) of the Company or a Related Corporation or a subset of such highly compensated employees. 

  
 3 

 (b)    The Board may provide that each person who, during the
course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under
that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that: 

(i)    the date on which such Purchase Right is granted will be the “Offering Date” of such Purchase
Right for all purposes, including determination of the exercise price of such Purchase Right; 
 (ii)    the
period of the Offering with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and 

(iii)    the Board may provide that if such person first becomes an Eligible Employee within a specified period of
time before the end of the Offering, he or she will not receive any Purchase Right under that Offering. 

(c)    No Employee will be eligible for the grant of any Purchase Rights if, immediately after any such Purchase
Rights are granted, such Employee owns stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any Related Corporation. For purposes of this Section 5(c), the rules of
Section 424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights and options will be treated as stock owned by such Employee. 

(d)    As specified by Section 423(b)(8) of the Code, an Eligible Employee may be granted Purchase Rights only
if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee’s rights to purchase stock of the Company or any Related
Corporation to accrue at a rate which, when aggregated, exceeds US $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined as of their respective Offering
Dates) for each calendar year in which such rights are outstanding at any time. 
 (e)    Officers of the Company
and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may (unless prohibited by law) provide in an Offering that
Employees who are highly compensated Employees within the meaning of Section 423(b)(4)(D) of the Code will not be eligible to participate. 

6.    PURCHASE RIGHTS; PURCHASE PRICE. 

(a)    On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a
Purchase Right to purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding 15% of such Employee’s earnings (as
defined by the Board in each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of
the Offering. 

  
 4 

 (b)    The Board will establish one or more Purchase Dates during
an Offering on which Purchase Rights granted for that Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering. 

(c)    In connection with each Offering made under the Plan, the Board may specify (i) a maximum number of
shares of Common Stock that may be purchased by any Participant on any Purchase Date during such Offering, (ii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering and/or
(iii) a maximum aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date under the Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted
under the Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant’s accumulated Contributions) allocation of the shares of Common Stock (rounded down to
the nearest whole share) available will be made in as nearly a uniform manner as will be practicable and equitable. 

(d)    The purchase price of shares of Common Stock acquired pursuant to Purchase Rights will be not less than the
lesser of: 
 (i)    an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the
Offering Date; or 
 (ii)    an amount equal to 85% of the Fair Market Value of the shares of Common Stock on the
applicable Purchase Date. 
 7.    PARTICIPATION; WITHDRAWAL; TERMINATION. 

(a)    An Eligible Employee may elect to participate in an Offering and authorize payroll deductions as the means of
making Contributions by completing and delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount
specified by the Board. Each Participant’s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law or regulations
requires that Contributions be deposited with a third party. If permitted in the Offering, a Participant may begin such Contributions with the first payroll occurring on or after the Offering Date (or, in the case of a payroll date that occurs after
the end of the prior Offering but before the Offering Date of the next new Offering, Contributions from such payroll will be included in the new Offering). If permitted in the Offering, a Participant may thereafter reduce (including to zero) or
increase his or her Contributions. If required under applicable law or regulations or if specifically provided in the Offering, in addition to or instead of making Contributions by payroll deductions, a Participant may make Contributions through the
payment by cash, check or wire transfer prior to a Purchase Date. 

  
 5 

 (b)    During an Offering, a Participant may cease making
Contributions and withdraw from the Offering by delivering to the Company a withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant’s Purchase
Right in that Offering will immediately terminate and the Company will distribute as soon as practicable to such Participant all of his or her accumulated but unused Contributions and such Participant’s Purchase Right in that Offering shall
thereupon terminate. A Participant’s withdrawal from that Offering will have no effect upon his or her eligibility to participate in any other Offerings under the Plan, but such Participant will be required to deliver a new enrollment form to
participate in subsequent Offerings. 
 (c)    Unless otherwise required by applicable law or regulations,
Purchase Rights granted pursuant to any Offering under the Plan will terminate immediately if the Participant either (i) is no longer an Employee for any reason or for no reason (subject to any post-employment participation period required by
law) or (ii) is otherwise no longer eligible to participate. The Company will distribute as soon as practicable to such individual all of his or her accumulated but unused Contributions. 

(d)    During a Participant’s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase
Rights are not transferable by a Participant, except by will, by the laws of descent and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section 10. 

(e)    Unless otherwise specified in the Offering or required by applicable law or regulations, the Company will
have no obligation to pay interest on Contributions. 
 8.    EXERCISE OF PURCHASE
RIGHTS. 
 (a)    On each Purchase Date, each Participant’s accumulated Contributions will
be applied to the purchase of shares of Common Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless
specifically provided for in the Offering. 
 (b)    Unless otherwise provided in the Offering, if any amount of
accumulated Contributions remains in a Participant’s account after the purchase of shares of Common Stock on the final Purchase Date of an Offering, then such remaining amount will not roll over to the next Offering and will instead be
distributed in full to such Participant after the final Purchase Date of such Offering without interest (unless otherwise required by applicable law or regulations). 

(c)    No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such
exercise under the Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities and other laws applicable to the Plan.
If on a Purchase Date the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date 

  
 6 

 
will be delayed until the shares of Common Stock are subject to such an effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be
more than 27 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares of Common Stock are not registered and the Plan is not in material compliance with all applicable laws and regulations, no
Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest. 

9.    COVENANTS OF THE COMPANY. 

The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the Plan
such authority as may be required to grant Purchase Rights and issue and sell shares of Common Stock thereunder unless the Company determines, in its sole discretion, that doing so would cause the Company to incur costs that are unreasonable. If,
after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially
reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of such Purchase Rights. 

10.    DESIGNATION OF BENEFICIARY. 

(a)    The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who
will receive any shares of Common Stock and/or Contributions from the Participant’s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. The Company may, but is not obligated
to, permit the Participant to change such designation of beneficiary. Any such designation and/or change must be on a form approved by the Company. 

(b)     If a Participant dies, and in the absence of a valid beneficiary designation, the Company will deliver any
shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the knowledge of the Company), the Company, in its sole discretion, may deliver
such shares of Common Stock and/or Contributions, without interest, to the Participant’s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.

 11.    ADJUSTMENTS UPON CHANGES IN COMMON
STOCK; CORPORATE TRANSACTIONS. 
 (a)    In the event of a
Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities by
which the share reserve is to increase automatically each year pursuant to Section 3(a), (iii) the class(es) and number of securities subject to, and the purchase price applicable to outstanding Offerings and Purchase Rights, and (iv) the
class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final, binding and conclusive. 

  
 7 

 (b)    In the event of a Corporate Transaction, then:
(i) any surviving corporation or acquiring corporation (or the surviving or acquiring corporation’s parent company) may assume or continue outstanding Purchase Rights or may substitute similar rights (including a right to acquire the same
consideration paid to the stockholders in the Corporate Transaction) for outstanding Purchase Rights, or (ii) if any surviving or acquiring corporation (or its parent company) does not assume or continue such Purchase Rights or does not
substitute similar rights for such Purchase Rights, then the Participants’ accumulated Contributions will be used to purchase shares of Common Stock (rounded down to the nearest whole share) within ten business days prior to the Corporate
Transaction under the outstanding Purchase Rights, and the Purchase Rights will terminate immediately after such purchase. 

12.    AMENDMENT, TERMINATION OR SUSPENSION OF
THE PLAN. 
 (a)    The Board may amend the Plan at any time in any respect the
Board deems necessary or advisable. However, except as provided in Section 11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by
applicable law, regulations or listing requirements. 
 (b)    The Board may suspend or terminate the Plan at any
time. No Purchase Rights may be granted under the Plan while the Plan is suspended or after it is terminated. 

(c)    Any benefits, privileges, entitlements and obligations under any outstanding Purchase Rights granted before
an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i) with the consent of the person to whom such Purchase Rights were granted, (ii) as necessary to
comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section 423 of the Code and the regulations and other interpretive guidance issued thereunder relating to Employee Stock
Purchase Plans) including without limitation any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii) as necessary to obtain or maintain favorable tax, listing, or regulatory
treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant’s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies with the requirements of Section 423 of the
Code. 
 13.    EFFECTIVE DATE OF PLAN. 

The Plan will become effective immediately prior to and contingent upon the IPO Date. No Purchase Rights will be exercised unless and until the
Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the Plan is adopted (or if required under Section 12(a) above, materially amended) by the Board. 

14.    MISCELLANEOUS PROVISIONS. 

(a)    Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of
the Company. 
 (b)    A Participant will not be deemed to be the holder of, or to have any of the rights of a
holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant’s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer agent). 

  
 8 

 (c)    The Plan and Offering do not constitute an employment
contract. Nothing in the Plan or in the Offering will in any way alter the at will nature of a Participant’s employment, if applicable, or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in
the employ of the Company or a Related Corporation, or on the part of the Company or a Related Corporation to continue the employment of a Participant. 

(d)    The provisions of the Plan will be governed by the laws of the State of Delaware without resort to that
state’s conflicts of laws rules. 
 (e)    If any particular provision of the Plan is found to be invalid or
otherwise unenforceable, such provision will not affect the other provisions of the Plan, but the Plan will be construed in all respects as if such invalid provision were omitted. 

(f)    If any provision of the Plan does not comply with applicable law or regulations, such provision shall be
construed in such a manner as to comply with applicable law or regulations. 
 15.    DEFINITIONS. 

As used in the Plan, the following definitions will apply to the capitalized terms indicated below: 

(a)    “Board” means the Board of Directors of the Company. 

(b)    “Capital Stock” means each and every class of common stock of the Company,
regardless of the number of votes per share. 
 (c)    “Capitalization Adjustment” means
any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through
merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in
corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion
of any convertible securities of the Company will not be treated as a Capitalization Adjustment. 

(d)    “Code” means the Internal Revenue Code of 1986, as amended, including any
applicable regulations and guidance thereunder. 
 (e)    “Committee” means
a committee of one or more members of the Board to whom authority has been delegated by the Board in accordance with Section 2(c). 

  
 9 

 (f)    “Common Stock” means, as of the
IPO Date, the common stock of the Company, having one vote per share. 
 (g)    “Company”
means Prevail Therapeutics Inc., a Delaware corporation. 
 (h)    “Contributions” means
the payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if
specifically provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions. 

(i)    “Corporate Transaction” means the consummation, in a single transaction or in a
series of related transactions, of any one or more of the following events: 
 (i)    a sale or other
disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; 

(ii)    a sale or other disposition of more than 50% of the outstanding securities of the Company; 

(iii)    a merger, consolidation or similar transaction following which the Company is not the surviving
corporation; or 
 (iv)    a merger, consolidation or similar transaction following which the Company is the
surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property,
whether in the form of securities, cash or otherwise. 
 (j)    “Director” means a
member of the Board. 
 (k)    “Eligible Employee” means an Employee who meets the
requirements set forth in the document(s) governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. 

(l)    “Employee” means any person, including an Officer or Director, who is
“employed” for purposes of Section 423(b)(4) of the Code by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an
“Employee” for purposes of the Plan. 
 (m)    “Employee Stock Purchase
Plan” means a plan that grants Purchase Rights intended to be options issued under an “employee stock purchase plan,” as that term is defined in Section 423(b) of the Code. 

(n)    “Exchange Act” means the Securities Exchange Act of 1934, as amended and the
rules and regulations promulgated thereunder. 

  
 10 

 (o)    “Fair Market Value” means, as of
any date, the value of the Common Stock determined as follows: 
 (i)    If the Common Stock is listed on any
established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume
of trading in the Common Stock) on the date of determination, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then
the Fair Market Value will be the closing sales price on the last preceding date for which such quotation exists. 

(ii)    In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board
in good faith in compliance with applicable laws and regulations and in a manner that complies with Sections 409A of the Code 

(iii)    Notwithstanding the foregoing, for any Offering that commences on the IPO Date, the Fair Market Value of
the shares of Common Stock on the Offering Date will be the price per share at which shares are first sold to the public in the Company’s initial public offering as specified in the final prospectus for that initial public offering. 

(p)    “IPO Date” means the date of the underwriting agreement between the Company
and the underwriters managing the initial public offering of the Common Stock, pursuant to which the Common Stock is priced for the initial public offering. 

(q)    “Offering” means the grant to Eligible Employees of Purchase Rights, with the
exercise of those Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the “Offering Document” approved by the Board for
that Offering. 
 (r)    “Offering Date” means a date selected by the Board for an
Offering to commence. 
 (s)    “Officer” means a person who is an officer
of the Company or a Related Corporation within the meaning of Section 16 of the Exchange Act. 

(t)    “Participant” means an Eligible Employee who holds an outstanding Purchase
Right. 
 (u)    “Plan” means this Prevail Therapeutics Inc. 2019 Employee Stock
Purchase Plan. 
 (v)    “Purchase Date” means one or more dates during an
Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. 

(w)    “Purchase Period” means a period of time specified within an Offering, generally
beginning on the Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. 

  
 11 

 (x)    “Purchase Right” means an
option to purchase shares of Common Stock granted pursuant to the Plan. 
 (y)    “Related
Corporation” means any “parent corporation” or “subsidiary corporation” of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.

 (z)    “Securities Act” means the Securities Act of 1933, as amended. 

(aa)    “Trading Day” means any day on which the exchange(s) or market(s) on which
shares of Common Stock are listed, including but not limited to the NYSE, Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. 

  
 12ONCOSEC
MEDICAL INCORPORATED

 

CHANGE
IN CONTROL PLAN

 

Effective
as of June 7, 2019

 

	1.0	PURPOSE
    OF PLAN
	 	 
	1.1	Purpose.
    The purposes of the OncoSec Medical, Inc. Change in Control Plan (the “Plan”) are to:
	 	 
	 	(a)	retain
    certain highly qualified individuals as employees of OncoSec, Inc. and/or its subsidiaries (the “Company”);
	 	 	 
	 	(b)	maintain
    the focus of such employees on the business of the Company and to mitigate the distractions caused by the possibility that
    the Company may be the target of an acquisition strategy; and
	 	 	 
	 	(c)	provide
    certain benefits to such employees if a Change in Control (as defined below) of the Company occurs and/or any employee’s
    employment is terminated in connection with such Change in Control.
	 	 
	 	The
    Plan is intended to be a “welfare plan,” but not a “pension plan,” as defined under Sections 3(1)
    and 3(2), respectively, of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).
	 	 
	2.0	DEFINITIONS
	 	 
	 	The
    following terms shall have the following meanings unless the context indicates otherwise:
	 	 
	2.1	“Beneficiary”
    shall mean a beneficiary designated in writing by a Participant to receive any Change in Control Termination Benefits
    in accordance with Section 6 below. If no beneficiary is designated by the Participant, then the Participant’s estate
    shall be deemed to be the Participant’s Beneficiary.
	 	 
	2.2	“Board”
    shall mean the Board of Directors of the Company.
	 	 
	2.3	“Cause”
    shall mean – unless otherwise defined in an employment agreement between the Participant and the Company or Subsidiary
    – a good faith determination by the Company that any of the following has occurred:

 

	 	(1)	The
    failure by Participant to substantially perform his/her assigned duties for the Company;
	 	 	 
	 	(2)	Participant
    engaging in conduct, which in the Company’s sole discretion, is materially injurious to the Company;
	 	 	 
	 	(3)	Behavior
    constituting gross negligence or willful misconduct by the Participant during the course of his/her duties;
	 	 	 
	 	(4)	The
    misappropriation of corporate assets or corporate opportunities by Participant or any other acts of dishonesty;
	 	 	 
	 	(5)	The
    breach of Participant’s fiduciary obligation to the Company;

 

	 	(6)	A
    material violation of any policy or procedure of the Company; or
	 	 	 
	 	(7)	The
    commission of, conviction of, pleading guilty to, or entering a plea of nolo contendere by Participant for any felony
    or any crime involving fraud, dishonesty, moral turpitude, or a breach of trust.

 

	2.4	“Change
    in Control” shall mean the occurrence of one of the following events:
	 	 
	 	(1)	during
    any consecutive 12-month period, individuals who, at the beginning of such period, constitute the Board of Directors of the
    Company (the “Incumbent Directors”) cease for any reason to constitute at least a majority of such Board, provided
    that any person becoming a director after the beginning of such 12-month period and whose election or nomination for election
    was approved by a vote of at least a majority of the Incumbent Directors then on the Board shall be an Incumbent Director;
    provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual
    or threatened election contest with respect to the election or removal of directors (“Election Contest”) or other
    actual or threatened solicitation of proxies or consents by or on behalf of any Person other than the Board (“Proxy
    Contest”), including by reason of any agreement intended to avoid or settle any Election Contest or Proxy Contest, shall
    be deemed an Incumbent Director; or

 

    	 	1	 

     

    

 

	 	(2)	any
    person becomes a Beneficial Owner, directly or indirectly, of either (A) 50% or more of the then-outstanding shares of common
    stock of the Company (“Company Common Stock”) or (B) securities of the Company representing 35% or more of the
    combined voting power of the Company’s then outstanding securities eligible to vote for the election of directors (the
    “Company Voting Securities”); provided, however, that for purposes of this subsection (2), the following acquisitions
    of Company Common Stock or Company Voting Securities shall not constitute a Change in Control: (w) an acquisition directly
    from the Company, (x) an acquisition by the Company or a Subsidiary, (y) an acquisition by any employee benefit plan (or related
    trust) sponsored or maintained by the Company or any Subsidiary, or (z) an acquisition pursuant to a Non-Qualifying Transaction
    (as defined in subsection (3) below); or
	 	 	 
	 	(3)	the
    consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction
    involving the Company or a Subsidiary (a “Reorganization”), or the sale or other disposition of all or substantially
    all of the Company’s assets (a “Sale”) or the acquisition of assets or stock of another corporation or other
    entity (an “Acquisition”), unless immediately following such Reorganization, Sale or Acquisition: (A) all or substantially
    all of the individuals and entities who were the Beneficial Owners, respectively, of the outstanding Company Common Stock
    and outstanding Company Voting Securities immediately prior to such Reorganization, Sale or Acquisition beneficially own,
    directly or indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting
    power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be,
    of the entity resulting from such Reorganization, Sale or Acquisition (including, without limitation, an entity which as a
    result of such transaction owns the Company or all or substantially all of the Company’s assets or stock either directly
    or through one or more subsidiaries, the “Surviving Entity”) in substantially the same proportions as their ownership,
    immediately prior to such Reorganization, Sale or Acquisition, of the outstanding Company Common Stock and the outstanding
    Company Voting Securities, as the case may be, and (B) no person (other than (x) the Company or any Subsidiary, (y) the Surviving
    Entity or its ultimate parent entity, or (z) any employee benefit plan (or related trust) sponsored or maintained by any of
    the foregoing) is the Beneficial Owner, directly or indirectly, of 35% or more of the total common stock or 35% or more of
    the total voting power of the outstanding voting securities eligible to elect directors of the Surviving Entity, and (C) at
    least a majority of the members of the board of directors of the Surviving Entity were Incumbent Directors at the time of
    the Board’s approval of the execution of the initial agreement providing for such Reorganization, Sale or Acquisition
    (any Reorganization, Sale or Acquisition which satisfies all of the criteria specified in (A), (B) and (C) above shall be
    deemed to be a “Non-Qualifying Transaction”); or

 

	 	(4)	approval
    by the stockholders of the Company of a complete liquidation or dissolution of the Company.
	 	 
	2.5	“Change
    in Control Date” shall mean the date that a Change in Control first occurs.
	 	 
	2.6	“Change
    in Control Equity Acceleration” shall mean the acceleration of vesting of outstanding equity awards described in
    Section 5 below.
	 	 
	2.7	“Change
    in Control Termination” shall mean a termination of the Participant’s employment:

 

	 	(1)	by
    the Company without Cause during the period beginning 3 months prior to the Change in Control Date and ending 18 months after
    the Change in Control Date, or
	 	 	 
	 	(2)	if
    the Participant has been designated by the Committee as a Tier 1 Participant or a Tier 2 Participant in accordance with Section
    3.2 below, by the Participant for Good Reason during the period beginning 3 months prior to the date of the Change in Control
    and ending 18 months after the Change in Control Date.
	 	 	 
	2.8	“Change
    in Control Termination Benefits” shall mean the benefits described in Section 6 below.
	 	 
	2.9	“Code”
    shall mean the Internal Revenue Code of 1986, as amended from time to time.
	 	 
	2.10	“Committee”
    shall mean (i) the Compensation Committee of the Board or (ii) a committee or subcommittee of the Board appointed by the
    Board from among its members.
	 	 
	2.11	“Company”
    shall mean OncoSec Medical, Inc., a Nevada corporation, including any successor entity or any successor to the assets
    of the Company that has assumed the Plan.
	 	 
	2.12	“Effective
    Date” shall mean the date the Board adopts the Plan.
	 	 
	2.13	“Employee”
    shall mean a regular full-time employee of the Company or any Subsidiary.

 

    	 	2	 

     

    

 

	2.14	“Good
    Reason” shall mean – unless otherwise defined in an employment agreement between the Participant and the Company
    or Subsidiary – the occurrence of any of the following within the 60-day period preceding a Termination Date:
	 	 
	 	(1)	a
    material adverse diminution of the Participant’s authority, duties or responsibilities, or the assignment to the Participant
    of authority, duties or responsibilities that are materially inconsistent with his or her titles, authority, duties and/or
    responsibilities in a manner materially adverse to the Participant; or
	 	 	 
	 	(2)	a
    material reduction in the Participant’s base salary or Target Annual Bonus without the Participant’s prior written
    consent (other than any reduction applicable to Employees generally); or
	 	 	 
	 	(3)	an
    actual change in the Participant’s principal work location by more than 75 miles and more than 75 miles from the Participant’s
    principal place of abode as of the date of such change in job location without the Participant’s prior written consent;
    or
	 	 	 
	 	(4)	a
    failure of any successor to the Company (whether through an asset sale or other sale of all or substantially all of the Company
    through which assumption of this Agreement would be required for it to remain in force after consummation of the sale) to
    assume this Plan and the Company’s obligations under this Plan.

 

	2.15	“Health
    Continuation Period” shall mean the period commencing on the Termination Date and continuing until the end of the
    applicable period as shown on Schedule A.
	 	 
	2.16	“
    Participant” shall mean any Employee who has been designated to participate in the Plan under Section 3 below.
	 	 
	2.17	“
    Plan” shall mean the OncSec Medical, Inc. Change in Control Plan.
	 	 
	2.18	“Salary”
    shall mean the highest annual base salary paid to the Participant during the 12-month period immediately preceding the
    earlier of (i) the Termination Date or the Change in Control Date, with such amount increased (if applicable) to take into
    account any elective or mandatory deferrals.

 

	2.19	“Severance
    Multiplier” shall mean the multiplier that shall be used to determine cash severance paid to a Participant in accordance
    with Schedule A and Section 6.2 below.
	 	 
	2.20	“Subsidiary”
    shall mean a corporation of which the Company directly or indirectly owns more than 50 percent of the “voting stock”
    (meaning the capital stock of any class or classes having general voting power under ordinary circumstances, in the absence
    of contingencies, to elect the directors of a corporation) or any other business entity in which the Company directly or indirectly
    has an ownership interest of more than 50 percent.
	 	 
	2.21	“Target
    Annual Bonus” means, with respect to any Participant, the Participant’s target bonus opportunity under the
    annual corporate incentive plan applicable to the Participant.
	 	 
	2.22	“Terminated
    Participant” shall mean a Participant whose employment with the Company and/or a Subsidiary has been terminated
    and which qualifies as a Change in Control Termination.
	 	 
	2.23	“Termination
    Date” shall mean the date a Terminated Participant’s employment with the Company and/or a Subsidiary is terminated.
	 	 
	2.24	“Tier
    1 Participant” shall mean a Participant who has been designated by the Committee as a Tier 1 Participant in accordance
    with Section 3.2 below.
	 	 
	2.25	“Tier
    2 Participant” shall mean a Participant who has been designated by the Committee as a Tier 2 Participant in accordance
    with Section 3.2 below.
	 	 
	2.26	“Tier
        3 Participant” shall mean a Participant who has been designated by the Committee as a Tier 3 Participant in
        accordance with Section 3.2 below.

         

	2.27	“Tier
        4 Participant” shall mean a Participant who has been designated by the Committee as a Tier 4 Participant in
        accordance with Section 3.2 below.

         

	3.0	ELIGIBILITY
    AND PARTICIPATION
	 	 
	3.1	Eligibility.
    All Employees of the Company shall be eligible to participate in the Plan.

 

    	 	3	 

     

    

 

	3.2	Participation.
    Participants shall consist of such Employees as the Committee in its sole discretion designates to participate in the Plan;
    provided, however, that the Committee shall not designate an Employee as a new Participant following a Change in Control
    Date. At the time the Committee designates an Employee as a Participant, the Committee shall also designate whether such Employee
    is a Tier 1 Participant, a Tier 2 Participant, a Tier 3 Participant or a Tier 4 Participant. The Committee may, in its sole
    discretion, terminate a Participant’s participation in the Plan at any time prior to the beginning of the 180-day period
    ending on the Change in Control Date.
	 	 
	4.0	ADMINISTRATION
	 	 
	4.1	Responsibility.
    The Committee shall have the responsibility, in its sole discretion, to control, operate, manage and administer the Plan
    in accordance with its terms.
	 	 
	4.2	Authority
    of the Committee. The Committee shall have the maximum discretionary authority permitted by law that may be necessary
    to enable it to discharge its responsibilities with respect to the Plan, including but not limited to the following:

 

	 	(a)	to
    determine eligibility for participation in the Plan;
	 	 	 
	 	(b)	to
    designate Participants;
	 	 	 
	 	(c)	to
    correct any defect, supply any omission, or reconcile any inconsistency in the Plan in such manner and to such extent as it
    shall deem appropriate in its sole discretion to carry the same into effect;
	 	 	 
	 	(d)	to
    issue administrative guidelines as an aid to administer the Plan and make changes in such guidelines as it from time to time
    deems proper;
	 	 	 
	 	(e)	to
    make rules for carrying out and administering the Plan and make changes in such rules as it from time to time deems proper;
	 	 	 
	 	(f)	to
    make reasonable determinations as to a Participant’s eligibility for benefits under the Plan, including determinations
    as to Cause and Good Reason; and
	 	 	 
	 	(g)	to
    take any and all other actions it deems necessary or advisable for the proper operation or administration of the Plan.

 

	4.3	Action
    by the Committee. The Committee may act only by a majority of its members. Any determination of the Committee may be made,
    without a meeting, by a writing or writings signed by all of the members of the Committee. In addition, the Committee may
    authorize any one or more of its members to execute and deliver documents on behalf of the Committee.
	 	 
	4.4	Delegation
    of Authority. The Committee may delegate to one or more of its members, or to one or more agents, such administrative
    duties as it may deem advisable; provided, however, that any such delegation shall be in writing. In addition, the
    Committee, or any person to whom it has delegated duties as aforesaid, may employ one or more persons to render advice with
    respect to any responsibility the Committee or such person may have under the Plan. The Committee may employ such legal or
    other counsel, consultants and agents as it may deem desirable for the administration of the Plan and may rely upon any opinion
    or computation received from any such counsel, consultant or agent. Expenses incurred by the Committee in the engagement of
    such counsel, consultant or agent shall be paid by the Company, or the Subsidiary whose employees have benefited from the
    Plan, as determined by the Committee.
	 	 
	4.5	Determinations
    and Interpretations by the Committee. All determinations and interpretations made by the Committee shall be binding and
    conclusive to the maximum extent permitted by law on all Participants and their heirs, successors, and legal representatives.
	 	 
	4.6	Liability.
    No member of the Board, no member of the Committee and no employee of the Company shall be liable for any act or failure to
    act hereunder, except in circumstances involving his or her bad faith, gross negligence or willful misconduct, or for any
    act or failure to act hereunder by any other member or employee or by any agent to whom duties in connection with the administration
    of the Plan have been delegated.
	 	 
	4.7	Indemnification.
    The Company shall indemnify members of the Committee and any agent of the Committee who is an employee of the Company, against
    any and all liabilities or expenses to which they may be subjected by reason of any act or failure to act with respect to
    their duties on behalf of the Plan, except in circumstances involving such person’s bad faith, gross negligence or willful
    misconduct.

 

    	 	4	 

     

    

 

	5.0	CHANGE
    IN CONTROL EQUITY ACCELERATION (SINGLE-TRIGGER)
	 	 
	5.1	Change
    in Control Equity Acceleration. Subject to Section 7.1, unvested equity rights held by Tier 1, Tier 2 and Tier 3 Participants
    shall be accelerated as follows: (i) outstanding stock options and other awards in the nature of rights that may be exercised
    shall become fully vested and exercisable, (ii) time-based restrictions on restricted stock, restricted stock units and other
    equity awards shall lapse and the awards shall become fully vested, and (iii) performance-based equity awards shall become
    vested and shall be deemed earned based on an assumed achievement of all relevant performance goals at “target”
    levels, and shall payout pro rata to reflect the portion of the performance period that had elapsed prior to the Change in
    Control. For avoidance of doubt, unvested equity rights held by Tier 4 Participants shall not be subject to the provisions
    of this Section 5.
	 	 
	6.0	CHANGE
    IN CONTROL TERMINATION BENEFITS (DOUBLE-TRIGGER)
	 	 
	6.1	Accrued
    Obligations. The Company shall pay to the Terminated Participant during the 30-day period following the Termination Date,
    a lump sum cash payment equal to the Participant’s earned but unpaid Salary, plus unreimbursed expenses, plus any and
    all other Company obligations that are accrued and due and owing to the Terminated Participant.
	 	 
	6.2	Cash
    Severance. Subject to Section 7.1, the Company shall pay to the Terminated Participant during the 60-day period following
    the later of the Change in Control Date or the Termination Date, a lump sum cash payment equal to the sum of:

 

	 	(a)	a
    pro rata Target Annual Bonus with respect to the year that the Termination Date occurs (pro rated to reflect the number of
    whole months between January 1 and the Termination Date), plus
	 	 	 
	 	(b)	(i)
    with respect to Tier 1, Tier 2, and Tier 3 Participants only, the product of (x) the Severance Multiplier times (y) the sum
    of the Terminated Participant’s (A) Salary plus (B) Target Annual Bonus with respect to the year that the Termination
    Date occurs, or
	 	 	 
	 	 	(ii)
    with respect to Tier 4 Participants only, the product of (x) the Severance Multiplier times (y) the sum of the Terminated
    Participant’s Salary.

 

	6.3	Welfare-Benefit
    Arrangements. Subject to Section 7.1, if the Terminated Participant elects to continue participation in the Company’s
    group health and welfare plans under COBRA, then during the Health Continuation Period as shown on Schedule A, or until Executive
    obtains other gainful employment and is covered by a health and medical plan, whichever occurs first, the Company shall pay
    or reimburse the Terminated Participant for the full cost of such coverage. Unless otherwise provided for in any written agreement
    between the Company and a Terminated Participant, or as otherwise agreed to by the Committee in its sole discretion, all other
    welfare benefits shall cease as of the Termination Date.
	 	 
	6.4	Payment
    of Change in Control Termination Benefits to Beneficiaries. In the event of the Terminated Participant’s death,
    all Change in Control Termination Benefits that would have been paid to the Terminated Participant under this Section 6 but
    for his or her death, shall be paid to the Terminated Participant’s Beneficiary.
	 	 
	6.5	Other
    Benefits. Notwithstanding anything contained in the Plan to the contrary, the Company or the Committee may, in its sole
    discretion, provide benefits in addition to the benefits described under this Section 6.

 

	7.0	PARTICIPANT
    OBLIGATIONS
	 	 
	7.1	Waiver
    and Release. As a condition precedent for receiving the Change in Control Equity Acceleration provided under Section 5
    above and the Change in Control Termination Benefits provided under Section 6 above, a Terminated Participant shall execute
    a waiver and release in a form acceptable to the Company. Such release must be executed and all revocation periods shall have
    expired within 60 days following the later of (x) the Change in Control Date or (y) the Termination Date; failing which Change
    in Control Termination Benefits (other than Accrued Obligations set forth under Section 6.1 above) shall be forfeited. If
    Change in Control Termination Benefits constitute non-exempt deferred compensation for purposes of Section 409A of the Code,
    and if such 60-day period begins in one calendar year and ends in the next calendar year, the payment or benefit shall not
    be made or commence before the second such calendar year, even if the release becomes irrevocable in the first such calendar
    year.
	 	 
	7.2	Enforcement.
    If a Terminated Participant violates or threatens to violate Section 7.2 or Section 7.3 above, the Company shall not have
    an adequate remedy at law. Accordingly, the Company shall be entitled to such equitable and injunctive relief as may be available
    to restrain the Terminated Participant and any business, firm, partnership, individual, corporation or entity participating
    in the breach or threatened breach from the violation of the provisions of Section 7.2 or 7.3 above. Nothing in the Plan shall
    be construed as prohibiting the Company from pursuing any other remedies available at law or in equity for breach or threatened
    breach of Section 7.2 or 7.3 above, including the recovery of damages.

 

    	 	5	 

     

    

 

	7.3	Confidentiality.
    At all times prior to and after the Change in Control Date, a Participant shall not disclose to anyone or make use of
    any trade secret or proprietary or confidential information of the Company, including such trade secret or proprietary or
    confidential information of any customer or other entity to which the Company owes an obligation not to disclose such information,
    which he or she acquires during his or her employment with the Company, including but not limited to records kept in the ordinary
    course of business, except:

 

	 	 	(i)	as
    such disclosure or use may be required or appropriate in connection with his or her work as an employee of the Company;
	 	 	 	 
	 	 	(ii)	when
    required to do so by a court of law, by any governmental agency having supervisory authority over the business of the Company
    or by any administrative or legislative body (including a committee thereof) with apparent jurisdiction to order him or her
    to divulge, disclose or make accessible such information;
	 	 	 	 
	 	 	(iii)	as
    to such confidential information that becomes generally known to the public or trade without his or her violation of this
    Section 7.5; or
	 	 	 	 
	 	 	(iv)	to
    the Participant’s spouse and/or his or her personal tax and financial advisors as reasonably necessary or appropriate
    to advance the Participant’s tax, financial and other personal planning (each an “Exempt Person”), provided,
    however, that any disclosure or use of any trade secret or proprietary or confidential information of the Company by an
    Exempt Person shall be deemed to be a breach of this Section 7.5 by the Participant.

 

	7.4	Return
    of Company Property. Immediately following the Termination Date, a Participant shall immediately return all Company property
    in his or her possession, including but not limited to all computer equipment (hardware and software), telephones, facsimile
    machines, palm pilots and other communication devices, credit cards, office keys, security access cards, badges, identification
    cards and all copies (including drafts) of any documentation or information (however stored) relating to the business of the
    Company, its customers and clients or its prospective customers and clients.
	 	 
	7.5	Cooperation.
    Following the Termination Date, a Participant shall give his or her assistance and cooperation willingly, upon reasonable
    advance notice with due consideration for his or her other business or personal commitments, in any matter relating to his
    or her position with the Company, or his or her expertise or experience as the Company may reasonably request, including his
    or her attendance and truthful testimony where deemed appropriate by the Company, with respect to any investigation or the
    Company’s defense or prosecution of any existing or future claims or litigations or other proceeding relating to matters
    in which he or she was involved or potentially had knowledge by virtue of his or her employment with the Company. In no event
    shall his or her cooperation materially interfere with his or her services for a subsequent employer or other similar service
    recipient. The Company agrees that (i) it will promptly reimburse the Terminated Participant for his or her reasonable and
    documented expenses in connection with his or her rendering assistance and/or cooperation under this Section 7.7, upon his
    or her presentation of documentation for such expenses and (ii) the Terminated Participant will be reasonably compensated
    for any continued material services as required under this Section 7.7.
	 	 
	8.0	CLAIMS
	 	 
	8.1	Claims
    Procedure. If any Participant or Beneficiary, or his or her legal representative, has a claim for benefits which is not
    being paid, such claimant may file a written claim with the Committee setting forth the amount and nature of the claim, supporting
    facts, and the claimant’s address. Written notice of the disposition of a claim by the Committee shall be furnished
    to the claimant within 90 days after the claim is filed. In the event of special circumstances, the Committee may extend the
    period for determination for up to an additional 90 days, in which case it shall so advise the claimant. If the claim is denied,
    the reasons for the denial shall be specifically set forth in writing, pertinent provisions of the Plan shall be cited, including
    an explanation of the Plan’s claim review procedure, and, if the claim is perfectible, an explanation as to how the
    claimant can perfect the claim shall be provided.
	 	 
	8.2	Claims
    Review Procedure. If a claimant whose claim has been denied wishes further consideration of his or her claim, he or she
    may request the Committee to review his or her claim in a written statement of the claimant’s position filed with the
    Committee no later than 60 days after receipt of the written notification provided for in Section 8.1 above. The Committee
    shall fully and fairly review the matter and shall promptly advise the claimant, in writing, of its decision within the next
    60 days. Due to special circumstances, the Committee may extend the period for determination for up to an additional 60 days.

 

	8.3	Dispute
Resolution. Any disputes arising under or in connection with the Plan shall be resolved by binding arbitration, to be held
in New York City in accordance with the rules and procedures of the American Arbitration Association. Judgment upon the award
rendered by the arbitrator may be entered in any court having jurisdiction thereof.

 

    	 	6	 

     

    

 

	8.4	Reimbursement
    of Expenses. If there is any dispute between the Company and a Participant with respect to a claim under the Plan, the
    Company shall reimburse such Participant all reasonable fees, costs and expenses incurred by such Participant with respect
    to such disputed claim; provided, however, that (i) such Participant is the prevailing party with respect to such disputed
    claim or (ii) the disputed claim is settled.

 

	9.0	TAXES
	 	 
	9.1	Withholding
    Taxes. The Company shall be entitled to withhold from any and all payments made to a Participant under the Plan all federal,
    state, local and/or other taxes or imposts which the Company determines are required to be so withheld from such payments
    or by reason of any other payments made to or on behalf of the Participant or for his or her benefit hereunder.
	 	 
	9.2	Mandatory
    Reduction of Payments in Certain Events.
	 	 
	 	(a)	Notwithstanding
    anything in this Plan to the contrary, in the event it shall be determined that any payment or distribution by the Company
    to or for the benefit of a Participant (whether paid or payable or distributed or distributable pursuant to the terms of this
    Plan or otherwise) (such benefits, payments or distributions are hereinafter referred to as “Payments”) would,
    if paid, be subject to the excise tax (the “Excise Tax”) imposed by Section 4999 of the Code, then, prior to the
    making of any Payments to the Participant, a calculation shall be made comparing (i) the net after-tax benefit to the Participant
    of the Payments after payment by the Participant of the Excise Tax, to (ii) the net after-tax benefit to the Participant if
    the Payments had been limited to the extent necessary to avoid being subject to the Excise Tax. If the amount calculated under
    (i) above is less than the amount calculated under (ii) above, then the Payments shall be limited to the extent necessary
    to avoid being subject to the Excise Tax (the “Reduced Amount”). The reduction of the Payments due hereunder,
    if applicable, shall be made by first reducing cash Payments and then, to the extent necessary, reducing those Payments having
    the next highest ratio of Parachute Value to actual present value of such Payments as of the date of the change in control
    transaction, as determined by the Determination Firm (as defined in Section 9.2(b) below). For purposes of this Section 9.2,
    present value shall be determined in accordance with Section 280G(d)(4) of the Code. For purposes of this Section 9.2, the
    “Parachute Value” of a Payment means the present value as of the date of the change in control transaction of
    the portion of such Payment that constitutes a “parachute payment” under Section 280G(b)(2) of the Code, as determined
    by the Determination Firm for purposes of determining whether and to what extent the Excise Tax will apply to such Payment.
	 	 	 
	 	(b)	All
    determinations required to be made under this Section 9.2, including whether an Excise Tax would otherwise be imposed, whether
    the Payments shall be reduced, the amount of the Reduced Amount, and the assumptions to be utilized in arriving at such determinations,
    shall be made by an independent, nationally recognized accounting firm or compensation consulting firm mutually acceptable
    to the Company and the Participant (the “Determination Firm”) which shall provide detailed supporting calculations
    both to the Company and the Participant within 15 business days after the receipt of notice from the Participant that a Payment
    is due to be made, or such earlier time as is requested by the Company. All fees and expenses of the Determination Firm shall
    be borne solely by the Company. Any determination by the Determination Firm shall be binding upon the Company and the Participant.
    As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by
    the Determination Firm hereunder, it is possible that Payments which the Participant was entitled to, but did not receive
    pursuant to Section 9.2(a), could have been made without the imposition of the Excise Tax (“Underpayment”), consistent
    with the calculations required to be made hereunder. In such event, the Determination Firm shall determine the amount of the
    Underpayment that has occurred and any such Underpayment shall be promptly paid by the Company to or for the benefit of the
    Participant but no later than March 15 of the year after the year in which the Underpayment is determined to exist, which
    is when the legally binding right to such Underpayment arises.

 

	 	(c)	In
    the event that the provisions of Code Section 280G and 4999 or any successor provisions are repealed without succession, this
    Section 9.2 shall be of no further force or effect.
	 	 
	9.3	Code
    Section 409A.
	 	 
	 	(a)	Notwithstanding
    anything in this Plan to the contrary, to the extent that any amount or benefit that would constitute non-exempt “deferred
    compensation” for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)
    would otherwise be payable or distributable hereunder by reason of a Participant’s termination of employment, such amount
    or benefit will not be payable or distributable to the Participant by reason of such circumstance unless (i) the circumstances
    giving rise to such termination of employment meet any description or definition of “separation from service”
    in Section 409A of the Code and applicable regulations (without giving effect to any elective provisions that may be available
    under such definition), or (ii) the payment or distribution of such amount or benefit would be exempt from the application
    of Section 409A of the Code by reason of the short-term deferral exemption or otherwise. This provision does not prohibit
    the vesting of any amount upon a termination of employment, however defined. If this provision prevents the payment or distribution
    of any amount or benefit, such payment or distribution shall be made on the date, if any, on which an event occurs that constitutes
    a Section 409A-compliant “separation from service.”

 

    	 	7	 

     

    

 

	 	b.	Notwithstanding
    anything in this Plan to the contrary, if any amount or benefit that would constitute non-exempt “deferred compensation”
    for purposes of Section 409A of the Code would otherwise be payable or distributable under this Plan by reason of a Participant’s
    separation from service during a period in which he or she is a Specified Employee (as defined below), then, subject to any
    permissible acceleration of payment by the Company under Treas. Reg. Section 1.409A-3(j)(4)(ii) (domestic relations order),
    (j)(4)(iii) (conflicts of interest), or (j)(4)(vi) (payment of employment taxes), the Participant’s right to receive
    payment or distribution of such non-exempt deferred compensation will be delayed until the earlier of the Participant’s
    death or the first business day of the seventh month following the Participant’s separation from service.
	 	 	 
	 	 	For
        purposes of this Plan, the term “Specified Employee” has the meaning given such term in Code Section 409A
        and the final regulations thereunder (“Final 409A Regulations”), provided, however, that, as permitted in
        the Final 409A Regulations, the Company’s Specified Employees and its application of the six-month delay rule of
        Code Section 409A(a)(2)(B)(i) shall be determined in accordance with rules adopted by the Company, which shall be applied
        consistently with respect to all nonqualified deferred compensation arrangements of the Company, including this Plan.

         

 

	9.4	No
    Guarantee of Tax Consequences. No person connected with the Plan in any capacity, including, but not limited to, the Company
    and any Subsidiary and their directors, officers, agents and employees makes any representation, commitment, or guarantee
    that any tax treatment, including, but not limited to, federal, state and local income, estate and gift tax treatment, will
    be applicable with respect to amounts deferred under the Plan, or paid to or for the benefit of a Participant under the Plan,
    or that such tax treatment will apply to or be available to a Participant on account of participation in the Plan.
	 	 
	10.0	TERM
    OF PLAN; AMENDMENT AND TERMINATION OF PLAN
	 	 
	10.1	Term
    of Plan. The Plan shall be effective as of the Effective Date and shall remain in effect until the Board terminates the
    Plan.
	 	 
	10.2	Amendment
    of Plan. The Plan may be amended by the Board at any time with or without prior notice; provided, however, that
    the Plan shall not be amended on a Change in Control Date or during the 3-year period following such Change in Control Date.
	 	 
	10.3	Termination
    of Plan. The Plan may be terminated or suspended by the Board at any time with or without prior notice; provided, however,
    that the Plan shall not be terminated or suspended on a Change in Control Date or during the 3-year period following such
    Change in Control Date.
	 	 
	10.4	No
        Adverse Effect. If the Plan is amended, terminated, or suspended in accordance with Sections 10.2 or 10.3 above, such
        action shall not adversely affect the benefits of any Participant.

         

	11.0	MISCELLANEOUS
	 	 
	11.1	Non-Duplication
    of Benefits. Change in Control Termination Benefits shall be reduced by any severance, layoff or termination payments
    or benefits made or provided by the Company or any Subsidiary to the Participant pursuant to (i) any severance plan, program,
    policy or arrangement of the Company or any Subsidiary not otherwise referred to in the Plan, (ii) any employment agreement
    between the Company or any Subsidiary and the Participant, and (iii) any federal, state or local statute, rule, regulation
    or ordinance.
	 	 
	11.2	No
    Right, Title, or Interest in Company Assets. Participants shall have no right, title, or interest whatsoever in or to
    any assets of the Company or any investments which the Company may make to aid it in meeting its obligations under the Plan.
    Nothing contained in the Plan, and no action taken pursuant to its provisions, shall create or be construed to create a trust
    of any kind, or a fiduciary relationship between the Company and any Participant, Beneficiary, legal representative or any
    other person. To the extent that any person acquires a right to receive payments from the Company under the Plan, such right
    shall be no greater than the right of an unsecured general creditor of the Company. Subject to this Section 11.2, all payments
    to be made hereunder shall be paid from the general funds of the Company and no special or separate fund shall be established
    and no segregation of assets shall be made to assure payment of such amounts; provided, however , that the Company
    may establish a grantor trust to provide for the payment of the benefits under the Plan of which the Company is the grantor
    within the meaning of subpart E, part I, subchapter J, chapter 1, subtitle A of the Code and under which the assets held by
    such trust will be subject to the claims of the Company’s general creditors under federal and state law in the event
    of the Company’s insolvency.
	 	 
	11.3	No
    Right to Continued Employment. The Participant’s rights, if any, to continue to serve the Company as an employee
    shall not be enlarged or otherwise affected by his or her designation as a Participant under the Plan, and the Company or
    the applicable Subsidiary reserves the right to terminate the employment of any employee at any time. The adoption of the
    Plan shall not be deemed to give any employee, or any other individual any right to be selected as a Participant or to continued
    employment with the Company or any Subsidiary.

 

    	 	8	 

     

    

 

	11.4	Other
    Rights. The Plan shall not affect or impair the rights or obligations of the Company or a Participant under any other
    written plan, contract, arrangement, or pension, profit sharing or other compensation plan.
	 	 
	11.5	Governing
    Law. The Plan shall be governed by and construed in accordance with the laws of the State of Nevada without reference
    to principles of conflict of laws, except as superseded by ERISA and other applicable federal law.
	 	 
	11.6	Severability.
    If any term or condition of the Plan shall be invalid or unenforceable to any extent or in any application, then the remainder
    of the Plan, with the exception of such invalid or unenforceable provision, shall not be affected thereby and shall continue
    in effect and application to its fullest extent.
	 	 
	11.7	Incapacity.
    If the Committee determines that a Participant or a Beneficiary is unable to care for his or her affairs because of illness
    or accident or because he or she is a minor, any benefit due the Participant or Beneficiary may be paid to the Participant’s
    spouse or to any other person deemed by the Committee to have incurred expense for such Participant (including a duly appointed
    guardian, committee or other legal representative), and any such payment shall be a complete discharge of the Company’s
    obligation hereunder.
	 	 
	11.8	Transferability
    of Rights. The Company shall have the unrestricted right to transfer its obligations under the Plan with respect to one
    or more Participants to any person, including, but not limited to, any purchaser of all or any part of the Company’s
    business. No Participant or Beneficiary shall have any right to commute, encumber, transfer or otherwise dispose of or alienate
    any present or future right or expectancy which the Participant or Beneficiary may have at any time to receive payments of
    benefits hereunder, which benefits and the right thereto are expressly declared to be non-assignable and nontransferable,
    except to the extent required by law. Any attempt to transfer or assign a benefit, or any rights granted hereunder, by a Participant
    or the spouse of a Participant shall, in the sole discretion of the Committee (after consideration of such facts as it deems
    pertinent), be grounds for terminating any rights of the Participant or Beneficiary to any portion of the Plan benefits not
    previously paid.

 

    	 	9	 

     

    

 

SCHEDULE
A

 

	TIER	 	SEVERANCE

    MULTIPLIER	 	HEALTH

    CONTINUATION

    PERIOD	 
	1	 	2.0x	 	24
    months	 
	2	 	1.5x	 	18
    months	 
	3	 	1.0x	 	12
    months	 
	4	 	0.5x	 	6
    months	 

 

Tier
participation:

 

Tier
1: CEO

Tier
2: All other “Chiefs”: CFO, COO, CSO, CCDO

Tier
3: Vice President and above

Tier
4: All other Participants

 

    	 	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]